Latest & greatest articles for glyburide

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on glyburide or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on glyburide and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for glyburide

1. Glibenclamide (Amglidia) - neonatal diabetes mellitus

Glibenclamide (Amglidia) - neonatal diabetes mellitus Published 07 October 2019 6 September 2019 ADVICE: in the absence of a submission from the holder of the marketing authorisation glibenclamide (Amglidia®) is not recommended for use within NHSScotland. Indication under review: Treatment of neonatal diabetes mellitus, for use in newborns, infants and children. The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we (...) not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer. Chairman Scottish Medicines Consortium Statement of advice SMC 2237 glibenclamide 0.6mg/mL , 6mg/mL oral suspension ( Amglidia ®) Amring Pharma www.scottishmedicines.org.uk

2019 Scottish Medicines Consortium

2. Effect of IV glyburide on adjudicated edema endpoints in the GAMES-RP Trial Full Text available with Trip Pro

Effect of IV glyburide on adjudicated edema endpoints in the GAMES-RP Trial In this secondary analysis of the Glyburide Advantage in Malignant Edema and Stroke (GAMES-RP) Trial, we report the effect of IV glyburide on adjudicated, edema-related endpoints.Blinded adjudicators assigned designations for hemorrhagic transformation, neurologic deterioration, malignant edema, and edema-related death to patients from the GAMES-RP phase II randomized controlled trial of IV glyburide for large (...) hemispheric infarct. Rates of these endpoints were compared between treatment arms in the per-protocol sample. In those participants with malignant edema, the effects of treatment on additional markers of edema and clinical deterioration were examined.In the per-protocol sample, 41 patients received glyburide and 36 received placebo. There was no difference in the frequency of hemorrhagic transformation (n = 24 [58.5%] in IV glyburide vs n = 23 [63.9%] in placebo, p = 0.91) or the incidence of malignant

2019 EvidenceUpdates

3. Glyburide

: November 2016 Full Text View Purpose This clinical trial aims to test whether glibenclamide is non-inferior to insulin for the treatment of gestational 2012 7. Glyburide Versus Metformin and Their Combination for the Treatment of Gestational Diabetes Mellitus: A Randomized Controlled Study. OBJECTIVE: To compare the efficacy and safety of glyburide versus metformin and their combination for the treatment of gestational diabetes mellitus (GDM). RESEARCH DESIGN AND METHODS: In this prospective randomized (...) Glyburide Top results for glyburide - Trip Database or use your Google+ account Liberating the literature ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3

2018 Trip Latest and Greatest

4. Glibenclamide (Amglidia) - Diabetes Mellitus

Glibenclamide (Amglidia) - Diabetes Mellitus 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5520 Send a question via our website www.ema.europa.eu/contact © European Medicines Agency, 2018. Reproduction is authorised provided the source is acknowledged. 22 February 2018 EMA/153558/2018 Committee for Medicinal Products for Human Use (CHMP) CHMP assessment report Amglidia International non (...) -proprietary name: glibenclamide Procedure No. EMEA/H/C/004379/0000 Note Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted. CHMP assessment report EMA/153558/2018 Page 2/60 Administrative information Name of the medicinal product: Amglidia Applicant: Ammtek 15, rue Beranger 75003 Paris FRANCE Active substance: GLIBENCLAMIDE International Nonproprietary Name: glibenclamide Pharmaco-therapeutic group (ATC Code): BLOOD GLUCOSE LOWERING DRUGS, EXCL

2018 European Medicines Agency - EPARs

5. Effect of Glyburide vs Subcutaneous Insulin on Perinatal Complications Among Women With Gestational Diabetes: A Randomized Clinical Trial. Full Text available with Trip Pro

Effect of Glyburide vs Subcutaneous Insulin on Perinatal Complications Among Women With Gestational Diabetes: A Randomized Clinical Trial. Randomized trials have not focused on neonatal complications of glyburide for women with gestational diabetes.To compare oral glyburide vs subcutaneous insulin in prevention of perinatal complications in newborns of women with gestational diabetes.The Insulin Daonil trial (INDAO), a multicenter noninferiority randomized trial conducted between May 2012 (...) and November 2016 (end of participant follow-up) in 13 tertiary care university hospitals in France including 914 women with singleton pregnancies and gestational diabetes diagnosed between 24 and 34 weeks of gestation.Women who required pharmacologic treatment after 10 days of dietary intervention were randomly assigned to receive glyburide (n=460) or insulin (n=454). The starting dosage for glyburide was 2.5 mg orally once per day and could be increased if necessary 4 days later by 2.5 mg and thereafter

2018 JAMA Controlled trial quality: predicted high

6. Glyburide, Gliclazide or Glimepiride for Elderly Patients with Type 2 Diabetes: An Updated Review of the Clinical Effectiveness and Safety

Glyburide, Gliclazide or Glimepiride for Elderly Patients with Type 2 Diabetes: An Updated Review of the Clinical Effectiveness and Safety Glyburide, Gliclazide or Glimepiride for Elderly Patients with Type 2 Diabetes: An Updated Review of the Clinical Effectiveness and Safety | CADTH.ca Find the information you need Glyburide, Gliclazide or Glimepiride for Elderly Patients with Type 2 Diabetes: An Updated Review of the Clinical Effectiveness and Safety Glyburide, Gliclazide or Glimepiride (...) for Elderly Patients with Type 2 Diabetes: An Updated Review of the Clinical Effectiveness and Safety Published on: August 20, 2015 Project Number: RC0693-000 Product Line: Research Type: Drug Report Type: Summary with Critical Appraisal Result type: Report Question What is the comparative clinical effectiveness of glyburide versus gliclazide or glimepiride in elderly patients with type 2 diabetes? What is the clinical evidence regarding the safety of glyburide, gliclazide or glimepiride in elderly

2015 Canadian Agency for Drugs and Technologies in Health - Rapid Review

7. Glibenclamide, metformin, and insulin for the treatment of gestational diabetes: a systematic review and meta-analysis. Full Text available with Trip Pro

Glibenclamide, metformin, and insulin for the treatment of gestational diabetes: a systematic review and meta-analysis. To summarize short term outcomes in randomized controlled trials comparing glibenclamide or metformin versus insulin or versus each other in women with gestational diabetes requiring drug treatment.Systematic review and meta-analysis.Randomized controlled trials that fulfilled all the following: (1) published as full text; (2) addressed women with gestational diabetes (...) requiring drug treatment; (3) compared glibenclamide v insulin, metformin v insulin, or metformin v glibenclamide; and (4) provided information on maternal or fetal outcomes.Medline, CENTRAL, and Embase were searched up to 20 May 2014.We considered 14 primary outcomes (6 maternal, 8 fetal) and 16 secondary (5 maternal, 11 fetal) outcomes.We analyzed 15 articles, including 2509 subjects. Significant differences for primary outcomes in glibenclamide v insulin were obtained in birth weight (mean difference

2015 BMJ

8. Systematic review with meta analysis: In women with gestational diabetes requiring drug treatment, glibenclamide may be inferior to insulin and metformin: metformin (plus insulin when required) performs better than insulin

Systematic review with meta analysis: In women with gestational diabetes requiring drug treatment, glibenclamide may be inferior to insulin and metformin: metformin (plus insulin when required) performs better than insulin In women with gestational diabetes requiring drug treatment, glibenclamide may be inferior to insulin and metformin: metformin (plus insulin when required) performs better than insulin | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our (...) or password? You are here In women with gestational diabetes requiring drug treatment, glibenclamide may be inferior to insulin and metformin: metformin (plus insulin when required) performs better than insulin Article Text Therapeutics/Prevention Systematic review with meta analysis In women with gestational diabetes requiring drug treatment, glibenclamide may be inferior to insulin and metformin: metformin (plus insulin when required) performs better than insulin Dana Carroll , Kristi W Kelley

2015 Evidence-Based Medicine

9. Glibenclamide

Glibenclamide USE OF GLIBENCLAMIDE IN PREGNANCY 0344 892 0909 USE OF GLIBENCLAMIDE IN PREGNANCY (Date of issue: August 2016 , Version: 2 ) This is a UKTIS monograph for use by health care professionals. For case-specific advice please contact UKTIS on 0344 892 0909. To report an exposure please download and complete a . Please encourage all women to complete an . Summary Glibenclamide is an oral sulfonylurea hypoglycaemic agent indicated in the treatment of non-insulin-dependent diabetes (...) in patients who fail to respond to dietary measures alone. Glibenclamide may be used in conjunction with metformin or insulin. Glibenclamide may be considered in the treatment of gestational diabetes where metformin is ineffective or not tolerated, and where treatment with insulin is declined. Data on the use of glibenclamide in pregnancy consist of >9,500 exposures, although as glibenclamide is used in the management of gestational diabetes, first trimester exposure data are lacking and an increased risk

2014 UK Teratology Information Service

10. Glyburide, gliclazide or glimepiride in the elderly with type 2 diabetes: a review of the clinical effectiveness and safety

Glyburide, gliclazide or glimepiride in the elderly with type 2 diabetes: a review of the clinical effectiveness and safety Glyburide, gliclazide or glimepiride in the elderly with type 2 diabetes: a review of the clinical effectiveness and safety Glyburide, gliclazide or glimepiride in the elderly with type 2 diabetes: a review of the clinical effectiveness and safety Canadian Agency for Drugs and Technologies in Health Record Status This is a bibliographic record of a published health (...) technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Canadian Agency for Drugs and Technologies in Health. Glyburide, gliclazide or glimepiride in the elderly with type 2 diabetes: a review of the clinical effectiveness and safety. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). 2011 Authors' conclusions There was no evidence identified concerning the clinical effectiveness of glyburide when

2011 Health Technology Assessment (HTA) Database.

11. Nateglinide provides tighter glycaemic control than glyburide in patients with Type 2 diabetes with prevalent postprandial hyperglycaemia. (Abstract)

Nateglinide provides tighter glycaemic control than glyburide in patients with Type 2 diabetes with prevalent postprandial hyperglycaemia. Postprandial hyperglycaemia in patients with Type 2 diabetes mellitus has been linked to the development of cardiovascular disease. This study compared the effects of mealtime (thrice-daily) nateglinide with once-daily glyburide on postprandial glucose levels in patients with Type 2 diabetes and postprandial hyperglycaemia.Patients with Type 2 diabetes aged (...) ≥ 21 years with 2-h postprandial glucose levels ≥ 11.1 mmol/l, HbA(1c) of 6.5-8.5% (48-69 mmol/mol) and BMI of 22-30 kg/m(2) were randomized to 6 weeks' double-blind treatment with nateglinide 120 mg three times daily prior to meals, or glyburide 5 mg once daily before breakfast. The primary endpoint was the baseline-adjusted change in plasma glucose from preprandial (fasting plasma glucose) to 2-h postprandial glucose levels (2-h postprandial glucose excursion) at 6 weeks.Patients were randomized

2011 EvidenceUpdates Controlled trial quality: uncertain

12. Cost-effectiveness analysis: Compared with glyburide, sitagliptin associated with incremental cost-effectiveness ratio of $169 572 per QALY and exenatide with $278 935 per QALY as second-line treatment in adult diabetics in the USA

Cost-effectiveness analysis: Compared with glyburide, sitagliptin associated with incremental cost-effectiveness ratio of $169 572 per QALY and exenatide with $278 935 per QALY as second-line treatment in adult diabetics in the USA Compared with glyburide, sitagliptin associated with incremental cost-effectiveness ratio of $169 572 per QALY and exenatide with $278 935 per QALY as second-line treatment in adult diabetics in the USA | BMJ Evidence-Based Medicine We use cookies to improve our (...) * Password * your user name or password? You are here Compared with glyburide, sitagliptin associated with incremental cost-effectiveness ratio of $169 572 per QALY and exenatide with $278 935 per QALY as second-line treatment in adult diabetics in the USA Article Text Therapeutics Cost-effectiveness analysis Compared with glyburide, sitagliptin associated with incremental cost-effectiveness ratio of $169 572 per QALY and exenatide with $278 935 per QALY as second-line treatment in adult diabetics

2010 Evidence-Based Medicine

13. Long-term costs and clinical outcomes associated with metformin-glibenclamide combination tablets (Glucovance) in patients with type 2 diabetes sub-optimally controlled by metformin: a modelling study in the French setting

Long-term costs and clinical outcomes associated with metformin-glibenclamide combination tablets (Glucovance) in patients with type 2 diabetes sub-optimally controlled by metformin: a modelling study in the French setting Long-term costs and clinical outcomes associated with metformin-glibenclamide combination tablets (Glucovance) in patients with type 2 diabetes sub-optimally controlled by metformin: a modelling study in the French setting Long-term costs and clinical outcomes associated (...) with metformin-glibenclamide combination tablets (Glucovance) in patients with type 2 diabetes sub-optimally controlled by metformin: a modelling study in the French setting Ray J A, Huet D, Valentine W J, Palmer A J, Cugnardey N, Renaudin C Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability

2008 NHS Economic Evaluation Database.

14. A Systematic Review and Meta-Analysis of Hypoglycemia and Cardiovascular Events: A comparison of glyburide with other secretagogues and with insulin. Full Text available with Trip Pro

A Systematic Review and Meta-Analysis of Hypoglycemia and Cardiovascular Events: A comparison of glyburide with other secretagogues and with insulin. OBJECTIVE: Glyburide is the most widely used sulfonylurea but has unique pharmacodynamic properties that may increase harm. We hypothesized that glyburide causes more hypoglycemia and cardiovascular events than other secretagogues or insulin. RESEARCH DESIGN AND METHODS: Data sources were Medline, Embase, Cochrane, and three other web-based (...) clinical trial registers (1966-2005). Parallel, randomized, controlled trials in people with type 2 diabetes comparing glyburide monotherapy with monotherapy using secretagogues or insulin were selected. Outcomes were hypoglycemia, glycemic control, cardiovascular events, body weight, and death. Titles and abstracts of 1,806 publications were reviewed in duplicate and 21 relevant articles identified. Data on patient characteristics, interventions, outcomes, and validity were extracted in duplicate

2007 EvidenceUpdates

15. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. Full Text available with Trip Pro

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. The efficacy of thiazolidinediones, as compared with other oral glucose-lowering medications, in maintaining long-term glycemic control in type 2 diabetes is not known.We evaluated rosiglitazone, metformin, and glyburide as initial treatment for recently diagnosed type 2 diabetes in a double-blind, randomized, controlled clinical trial involving 4360 patients. The patients were treated for a median of 4.0 years (...) . The primary outcome was the time to monotherapy failure, which was defined as a confirmed level of fasting plasma glucose of more than 180 mg per deciliter (10.0 mmol per liter), for rosiglitazone, as compared with metformin or glyburide. Prespecified secondary outcomes were levels of fasting plasma glucose and glycated hemoglobin, insulin sensitivity, and beta-cell function.Kaplan-Meier analysis showed a cumulative incidence of monotherapy failure at 5 years of 15% with rosiglitazone, 21% with metformin

2006 NEJM Controlled trial quality: predicted high

16. Reversal of life-threatening, drug-related potassium-channel syndrome by glibenclamide. (Abstract)

Reversal of life-threatening, drug-related potassium-channel syndrome by glibenclamide. We describe three critically ill patients who received drugs with K(ATP) channel-opening properties and subsequently developed severe life-threatening complications, including hyperkalaemia and cardiovascular disturbances. Administration of the sulfonylurea-receptor inhibitor glibenclamide promptly reversed these abnormalities. Over the past 3 years, we have seen this syndrome and response in five patients

2005 Lancet

17. A comparison of glyburide and insulin in women with gestational diabetes mellitus. (Abstract)

A comparison of glyburide and insulin in women with gestational diabetes mellitus. Women with gestational diabetes mellitus are rarely treated with a sulfonylurea drug, because of concern about teratogenicity and neonatal hypoglycemia. There is little information about the efficacy of these drugs in this group of women.We studied 404 women with singleton pregnancies and gestational diabetes that required treatment. The women were randomly assigned between 11 and 33 weeks of gestation to receive (...) glyburide or insulin according to an intensified treatment protocol. The primary end point was achievement of the desired level of glycemic control. Secondary end points included maternal and neonatal complications.The mean (+/-SD) pretreatment blood glucose concentration as measured at home for one week was 114+/-19 mg per deciliter (6.4+/-1.1 mmol per liter) in the glyburide group and 116+/-22 mg per deciliter (6.5+/-1.2 mmol per liter) in the insulin group (P=0.33). The mean concentrations during

2000 NEJM Controlled trial quality: uncertain

18. Cost-effectiveness analyses of the conversion of patients with non-insulin-dependent diabetes mellitus from glipizide to glyburide and of the accompanying pharmacy follow-up clinic

Cost-effectiveness analyses of the conversion of patients with non-insulin-dependent diabetes mellitus from glipizide to glyburide and of the accompanying pharmacy follow-up clinic Cost-effectiveness analyses of the conversion of patients with non-insulin-dependent diabetes mellitus from glipizide to glyburide and of the accompanying pharmacy follow-up clinic Cost-effectiveness analyses of the conversion of patients with non-insulin-dependent diabetes mellitus from glipizide to glyburide (...) ) glyburide therapy; (3) glyburide therapy and the accompanying pharmacy follow-up clinic. Type of intervention Secondary prevention. Economic study type Cost-effectiveness analysis. Study population Patients with non-insulin dependent diabetes mellitus, of whom 98.5% were men, with average age 65.11 (+ Setting Primary care/pharmacist setting . The economic study was carried out in Ohio, USA. Dates to which data relate The effectiveness and resource data related to 1993.1994 prices were used. Source

1995 NHS Economic Evaluation Database.

19. Muslims with non-insulin dependent diabetes fasting during Ramadan: treatment with glibenclamide. Full Text available with Trip Pro

Muslims with non-insulin dependent diabetes fasting during Ramadan: treatment with glibenclamide. To compare the efficacy of two glibenclamide regimens in patients with non-insulin dependent diabetes who were fasting during Ramadan and regular glibenclamide treatment in the non-fasting group.Non-randomised control group of patients who did not fast during Ramadan and two groups of patients who fasted randomised equally to one of two regimens: to take their usual morning dose of glibenclamide (...) in the evening and their usual evening dose before dawn; or to follow this pattern but to reduce the total dose by a quarter.Two university hospitals, one private hospital, and two private clinics in Casablanca and Rabat, Morocco.591 diabetic patients (198 men, 391 women, two unspecified) with similar duration of diabetes and length and amount of glibenclamide treatment, of whom 542 completed the study.Serum fructosamine and total glycated haemoglobin concentrations and number of hypoglycaemic events.At

1993 BMJ Controlled trial quality: uncertain